Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

BACKGROUND: In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immune reconstitution inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Kityo, Cissy, Szubert, Alexander J., Siika, Abraham, Heyderman, Robert, Bwakura-Dangarembizi, Mutsa, Lugemwa, Abbas, Mwaringa, Shalton, Griffiths, Anna, Nkanya, Immaculate, Kabahenda, Sheila, Wachira, Simon, Musoro, Godfrey, Rajapakse, Chatu, Etyang, Timothy, Abach, James, Spyer, Moira J., Wavamunno, Priscilla, Nyondo-Mipando, Linda, Chidziva, Ennie, Nathoo, Kusum, Klein, Nigel, Hakim, James, Gibb, Diana M., Walker, A. Sarah, Pett, Sarah L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279020/
https://www.ncbi.nlm.nih.gov/pubmed/30513108
http://dx.doi.org/10.1371/journal.pmed.1002706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279020/
https://www.ncbi.nlm.nih.gov/pubmed/30513108
http://dx.doi.org/10.1371/journal.pmed.1002706

Ejemplares similares